Mineralocorticoid receptor (MR) antagonists, including spironolactone and eplerenone, are fundamental drugs in HF management, as they partly inhibit NOX activity to reduce oxidative stress (Nagata et al., 2006). Here, NR3C2 is linked to hydrops fetalis.